Literature DB >> 19385471

Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.

Farhan Fateh Jang1, Wang Wei, Wang Mao De.   

Abstract

BACKGROUND: Astrocytoma is the most malignant intracranial neoplasm and is characterized by high neovascularization and peritumoural brain oedema. Angiogenesis is a complicated process in oncogenesis regulated by the balance between angiogenic and antiangiogenic factors.
METHODS: The expression of two angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor were investigated using immunohistochemistry for astrocytoma from 82 patients and 11 normal human tissues.
RESULTS: The expression of vascular endothelial growth factor and basic fibroblast growth factor positively correlate with the pathological grade of astrocytoma, microvessel density numbers and brain oedema, which may be responsible for the increased tumour neovascularization and peritumoural brain oedema.
CONCLUSION: The results support the idea that inhibiting vascular endothelial growth factor and basic fibroblast growth factor are useful for the treatment of human astrocytoma and to improve patient's clinical outcomes and prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19385471

Source DB:  PubMed          Journal:  J Ayub Med Coll Abbottabad        ISSN: 1025-9589


  2 in total

1.  Intratumoral hemorrhage-related differences in the expression of vascular endothelial growth factor, basic fibroblast growth factor and thioredoxin reductase 1 in human glioblastoma.

Authors:  Bulent Kaya; Onur Çiçek; Fatih Erdi; Siddika Findik; Yasar Karatas; Hasan Esen; Fatih Keskin; Erdal Kalkan
Journal:  Mol Clin Oncol       Date:  2016-08-02

2.  Immunohistochemical Expression of Ki-67, PCNA and CD34 in Astrocytomas: A Clinicopathological Study.

Authors:  Mohammed Kassim Chaloob; Hussam Hasson Ali; Ban Jumaa Qasim; Ahmed Salahaldeen Mohammed
Journal:  Oman Med J       Date:  2012-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.